Stock EGRX EAGLE PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Real-time Estimate Cboe BZX
Other stock markets
 10:14:21 2024-06-10 am EDT 		5-day change 1st Jan Change
3.54 USD -4.58% Intraday chart for Eagle Pharmaceuticals, Inc. -4.99% -30.78%
May. 15 Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement CI
May. 06 North American Morning Briefing : Stock Futures -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Eagle Pharmaceuticals CFO Resigns; Shares Fall
Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes
Eagle Pharmaceuticals Idles 36% Workforce -- Shares Down
Sector Update: Health Care Stocks Mixed Late Afternoon
Top Midday Decliners
Eagle Pharmaceuticals Receives Non-Compliance Notice From Nasdaq After Delay in Filing Quarterly Report
Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer
Eagle Pharmaceuticals, Inc. Announces Management Change
Sector Update: Health Care Stocks Falling Late Afternoon
Sector Update: Health Care Stocks Easing Thursday Afternoon
Eagle Pharmaceuticals Delays Q3 Earnings Results; Shares Fall
Eagle Pharmaceuticals, Inc. Announces Delay in Third Quarter 2023 Results
Eagle Pharmaceuticals Granted Patent for Cancer Treatment Pemfexy
Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc
Eagle Pharmaceuticals Insider Sold Shares Worth $300,026, According to a Recent SEC Filing
Eagle Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Edge Higher Premarket Monday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EGRX Stock
  4. News Eagle Pharmaceuticals, Inc.
  5. Other languages